2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.43 Savolitinib and Third-Generation EGFR-TKI Therapy in EGFRm, MET-Altered NSCLC Patients: A Case Series

EP.12A.43 Savolitinib and Third-Generation EGFR-TKI Therapy in EGFRm, MET-Altered NSCLC Patients: A Case Series

Pdf Summary

The document is a case series study titled "Savolitinib and Third-Generation EGFR-TKI Therapy in EGFRm, MET-Altered NSCLC Patients," focusing on the use of savolitinib combined with third-generation EGFR-TKIs in patients with non-small cell lung cancer (NSCLC) with EGFR mutations and MET alterations. This approach addresses resistance mechanisms in patients previously treated with EGFR-TKIs. The study explores the outcomes of this combination therapy on three patients, examining its efficacy and safety.<br /><br />MET alterations, including exon 14 skipping and amplification, are significant as they contribute to resistance against EGFR-TKI treatments in NSCLC patients. The combination of EGFR-TKIs and MET-TKIs, like savolitinib, is proposed as a promising method to counteract this resistance.<br /><br />**Methods and Results:**<br />Three patients received the combination therapy:<br />- **Patient 1**: A 70-year-old male with advanced sarcomatoid lung cancer showed a progression-free survival (PFS) of 16 months with mild adverse effects.<br />- **Patient 2**: A 50-year-old non-smoking female with adenocarcinoma developed brain metastases post-treatment with gefitinib and osimertinib. After transitioning to savolitinib and EGFR-TKI therapy, the patient achieved a PFS of 19 months.<br />- **Patient 3**: A 35-year-old male with adenocarcinoma and smoking history received osimertinib but progressed after 13 months. Following several treatment lines, including the study therapy, he experienced partial response with a 7-month PFS.<br /><br />The study concludes that the dual-target treatment appears effective and emphasizes the necessity for comprehensive testing of MET alterations. Future research is recommended to further explore this therapeutic approach across different subtypes of mutations and to validate these findings in a broader patient cohort.

Asset Subtitle

Xixi Lai

Meta Tag

Speaker Xixi Lai

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Savolitinib

EGFR-TKI

NSCLC

MET alterations

resistance mechanisms

combination therapy

progression-free survival

adenocarcinoma

sarcomatoid lung cancer

brain metastases